Rede D'Or São Luiz stock
RDOR3.SASAORede D'Or São Luiz S.A., HealthcareISIN BRRDORACNOR8
62Score 62 out of 100, Neutral
Price and trend
43 / 100
Price history
−27% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 8.4% below it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 21).
The price is 28% below its 52-week high. Largest decline in 6 years: 73% (August 2021 to March 2023).
Chart figures for advanced users
- SMA 50$6.82
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)21
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.57
- The lowest closing price of the last twelve months.
- Resistance$8.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Rede D'Or São Luiz S.A. belongs to the Medical (Care Facilities) industry (Brazil) and, with a market value of $13.29B, is number 5 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $9.92B (up 10.2% year on year) and earnings of $834.7M (up 21.9%).
- For fiscal 2026, analysts expect on average revenue of $10.83B (up 9.2%) and adjusted earnings per share of $0.39 (up 5.7%).
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 243 of 702 in Healthcare, median 53.
- The P/E is 15.5 (Medical (Care Facilities) median 55.2, own median of recent years 29.6).
- Our model puts fair value at $12.55, with the price 51% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 57.3% a year since 2020.Growth 88
- Modestly valuedP/E 15.5, Medical (Care Facilities) median 55.2, own median 29.6.Valuation 92
- Growing faster than its industryRevenue up 31.8% a year since 2020, Healthcare sector median 12.1%.Growth 88
Weaknesses
- High debtDebt 2.39 times equity (latest quarter), Healthcare sector median 0.12.Stability 46
- Negative free cash flowFree cash flow −$725.32M over the last 12 months.Fundamentals 64
- Interest barely coveredOperating profit covers interest only 1.9 times.Stability 46
Its standout strengths are valuation and growth, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $8.96 and expensive above $20.91 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $3.36 (cash-flow model) and $21.74 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 15%. At 16% the fair value would be $12.33, at 14% it would be $12.84.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (55.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 9.4% on the twelve months before. Revenue has grown strongly since 2013, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 21%, operating 18%, net 8%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 30 Mar 2027in 137 days
- Last reported
- 12 Aug 2026EPS reported $0.10 (expected $0.09)above expectations
Analyst estimates
Earnings estimates have barely changed since 25 Oct 2026.
- Earnings per share
- $0.39+0.3%
- Revenue
- $10.83B0.0%
- Earnings per share
- $0.48+0.3%
- Revenue
- $11.91B+0.2%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Rede D'Or São Luiz
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- HCA HealthcareHCA $104.58B75
- Fresenius SE & Co. KGaAFRE.DE $33.26B56
- Tenet HealthcareTHC $22.83B76
- Encompass HealthEHC $13.82B75
- Apollo Hospitals EnterpriseAPOLLOHOSP.NS $13.01B70
- Aier Eye Hospital Group300015.SZ $12.04B66
- Universal Health ServicesUHS $11.4B73
- Fresenius Medical Care AG & Co. KGaAFME.DE $11.38B57
ETFs that hold Rede D'Or São Luiz
Held by 43 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Franklin FTSE Brazil UCITS ETF USDFLXB | 1.10% | 0.19% | €244.05M |
| iShares MSCI Brazil UCITS ETF USD (Dist)IQQB | 1.07% | 0.74% | €409.4M |
| Invesco FTSE Emerging Markets High Dividend Low Volatility UCITS ETFEHDL | 0.89% | 0.49% | €264.54M |
Show 5 more
| iShares MSCI EM Latin America UCITS ETF USDIUSC | 0.54% | 0.20% | €1.73B |
| iShares Ageing Population UCITS ETF2B77 | 0.43% | 0.40% | €813.42M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.19% | 0.60% | €31.52M |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.11% | 0.32% | €17.98M |
| Xtrackers MSCI Emerging Markets ESG UCITS ETF 1CXZEM | 0.09% | 0.25% | €1.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = R$5.6169)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.